These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

985 related items for PubMed ID: 24456065

  • 1. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
    Takahashi N, Koh T, Tominaga Y, Saito Y, Kashimoto Y, Matsumura T.
    World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study.
    Casas M, Rösler M, Sandra Kooij JJ, Ginsberg Y, Ramos-Quiroga JA, Heger S, Berwaerts J, Dejonckheere J, van der Vorst E, Schäuble B.
    World J Biol Psychiatry; 2013 May; 14(4):268-81. PubMed ID: 22106853
    [Abstract] [Full Text] [Related]

  • 3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S.
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 5. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A, Richard C, Prinzo R, Binder C.
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [Abstract] [Full Text] [Related]

  • 6. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
    Buitelaar JK, Sobanski E, Stieglitz RD, Dejonckheere J, Waechter S, Schäuble B.
    J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962
    [Abstract] [Full Text] [Related]

  • 7. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.
    Buitelaar JK, Casas M, Philipsen A, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, van Oene JC, Schäuble B.
    Psychol Med; 2012 Jan; 42(1):195-204. PubMed ID: 21733214
    [Abstract] [Full Text] [Related]

  • 8. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
    Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Bloomfield R, Squires LA, Coghill DR.
    CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
    [Abstract] [Full Text] [Related]

  • 9. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK.
    Biol Psychiatry; 2008 May 15; 63(10):981-9. PubMed ID: 18206857
    [Abstract] [Full Text] [Related]

  • 10. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM.
    Arch Pediatr Adolesc Med; 2006 Jan 15; 160(1):82-90. PubMed ID: 16389216
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB, Nordbrock E, Adjei AL, Childress A, Kupper RJ, Greenhill L.
    CNS Drugs; 2015 Apr 15; 29(4):331-40. PubMed ID: 25877989
    [Abstract] [Full Text] [Related]

  • 12. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.
    Zheng Y, Wang YF, Qin J, Wang LW, Zou LP, Jin XM, Xu T, Wang Y, Qi YL, Gong ME, Yin QY, Mai JN, Jing J, Luo XY, Ma HW, Li HB, Xie L, Li Y, Kuang GF, Yi MJ, Wang F, Zhu XH, Yao YB.
    Chin Med J (Engl); 2011 Oct 15; 124(20):3269-74. PubMed ID: 22088519
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD.
    Buitelaar JK, Trott GE, Hofecker M, Waechter S, Berwaerts J, Dejonkheere J, Schäuble B.
    Int J Neuropsychopharmacol; 2012 Feb 15; 15(1):1-13. PubMed ID: 21798108
    [Abstract] [Full Text] [Related]

  • 14. Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate.
    Rösler M, Ginsberg Y, Arngrim T, Adamou M, Niemelä A, Dejonkheere J, van Oene J, Schäuble B.
    World J Biol Psychiatry; 2013 May 15; 14(4):282-90. PubMed ID: 21517701
    [Abstract] [Full Text] [Related]

  • 15. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI, Bijlenga D, Boonstra AM, Breuk M, Pardoen WF, Beekman AT, Kooij JJ.
    Eur Neuropsychopharmacol; 2014 Apr 15; 24(4):519-28. PubMed ID: 24508533
    [Abstract] [Full Text] [Related]

  • 16. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L.
    Eur Neuropsychopharmacol; 2013 Oct 15; 23(10):1208-18. PubMed ID: 23332456
    [Abstract] [Full Text] [Related]

  • 17. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T.
    Biol Psychiatry; 2006 May 01; 59(9):829-35. PubMed ID: 16373066
    [Abstract] [Full Text] [Related]

  • 18. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
    Rösler M, Retz W, Fischer R, Ose C, Alm B, Deckert J, Philipsen A, Herpertz S, Ammer R.
    World J Biol Psychiatry; 2010 Aug 01; 11(5):709-18. PubMed ID: 20353312
    [Abstract] [Full Text] [Related]

  • 19. Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD.
    Biederman J, Mick E, Fried R, Wilner N, Spencer TJ, Faraone SV.
    Eur Neuropsychopharmacol; 2011 Jul 01; 21(7):508-15. PubMed ID: 21303732
    [Abstract] [Full Text] [Related]

  • 20. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE.
    Can J Clin Pharmacol; 2006 Jul 01; 13(1):e50-62. PubMed ID: 16456216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.